InsidersTradesSigma
Fulcrum Therapeutics, Inc.: management transactions · United States · SEC (Form 4)
SEC:fulcrum-therapeutics-incUS·SEC (Form 4)Mcap 446M€Healthcare & Pharma
Browse the full management transaction log of Fulcrum Therapeutics, Inc., a listed equity based in United States. Shares trade on US US, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Fulcrum Therapeutics, Inc. has published 31 public disclosures. Market capitalisation: €445.8m. The latest transaction was filed on 4 February 2026 — Cession. Among the most active insiders: Gould Robert J. Every trade is openly available.
31
Insider Decl.
0
Thresholds
€221,611
8 ops.
Buy Volume
€852,213
6 ops.
Sell Volume
Financial data
Analyst consensus
10 analystsBuy
8.00 €Target 18.90 €25.00 €
Income statement
Net income−74.9 M€0.0% margin
Valuation
PER (forward)-5.0x
P/Book1.3x
Beta3.01
Balance sheet & cash
Market cap445.8 M€
Total debt6.4 M€
Free Cash Flow−60.4 M€
Debt / Equity2%
Profitability & ownership
ROE-27.1%
ROA-18.4%
% insiders3.9%
% institutions109.7%
Last declaration on 4 February 2026
Declarations0 total
No declarations found
0 of 0 declarations
About Fulcrum Therapeutics, Inc.
Geographically, Fulcrum’s operating footprint is concentrated in the Boston/Cambridge biotech cluster, where it maintains its headquarters and laboratory space. That location provides access to talent, academic networks, and the broader U.S. life sciences ecosystem, but the company remains primarily a research and development organization with limited commercial infrastructure. Recent highlights include positive updates from the Phase 1b PIONEER study of pociredir in SCD, plans to advance toward a potential registration-enabling trial in the second half of 2026, and a stronger cash position at the end of 2025 following a public equity offering. Overall, Fulcrum remains a high-risk, high-upside rare-disease biotech listed on the NASDAQ Global Market in the United States.
